Xin Lang Cai Jing·2025-11-10 05:57Core Insights - The 8th China International Import Expo (CIIE) is being held from November 5 to 10 in Shanghai, showcasing a record scale of new products, technologies, and services, serving as a platform for global innovation collaboration and trade cooperation [1][2] - Bayer Health Consumer Products emphasizes an "open" innovation attitude, focusing on consumer-centric local collaborative innovations through its China Innovation Cooperation Center (CCIP) [1][2] Group 1: Event Overview - The CIIE has evolved from primarily introducing foreign products to a broader platform for value co-creation, including technology exchanges and cross-industry collaborations [2] - Bayer has established multiple significant agreements at the CIIE, launching several "CIIE babies," including two global firsts: Daxie® Lactulose Oral Solution and Beilexin® B5 Essence Diaper Cream [2] Group 2: AI Technology Application - Bayer is actively building an AI-driven innovation ecosystem in the health consumer sector, focusing on enhancing data foundations to improve business insights [4][5] - The company hosted a forum discussing how AI can meet consumer health needs and optimize the health consumer industry [5][6] Group 3: Consumer-Centric Innovation - With rising self-care demands, Bayer is restructuring its product and supply chain strategies to focus on consumer needs, establishing the CCIP to foster integrated innovation [8][9] - The Beilexin® B5 Essence Diaper Cream is a product developed through the CCIP, tailored to the specific needs of Chinese infants [9] Group 4: Manufacturing and Supply Chain - Bayer is investing 750 million yuan in a new supply center in Qidong, expected to be operational by 2028, to enhance production capacity for both domestic and export markets [11] - The company is shifting its channel strategy towards a "platform + pharmacy" model, collaborating with JD Health for comprehensive channel management [11][12] Group 5: Localization Strategy - Bayer's approach reflects a typical path for multinational companies adapting to the Chinese market, combining global experience with local insights through partnerships with local innovators and platforms [12]